Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Arcadia Biosciences Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Arcadia Biosciences Inc (RKDA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026
Competitors Tracked
14
Publicly traded peers
Peer Group Market Share
0.01 %
vs 0.01 % a year ago
Revenue Growth Y/Y
-0.82 %
Peers: -3.76 %
Net Margin
-434.23 %
Peers: 28.01 %

Key Findings: Arcadia Biosciences Inc vs Its Competitors

  • TTM: Trailing 12-month revenue of 5M vs 82,874M combined for tracked competitors (0.0% combined share).
  • Trending: Latest-quarter revenue run-rate is accelerating (+21.6% annualized vs trailing 12 months), vs accelerating (+11.3%) for its tracked peer group.
  • Growth: Arcadia Biosciences Inc generated -0.8% revenue growth year over year in Q2 2026, vs -3.8% for its tracked competitors combined.
  • Profitability: Its -434.2% net margin compares with 28.0% for the peer group.
  • Scale: Arcadia Biosciences Inc ranks #109 of 134 companies by market capitalization in the Oil And Gas Production industry, holding 0.0% of industry market cap.
  • Peer revenue share: Arcadia Biosciences Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
  • Peer differentiation: Revenue per employee of $0.59M compares with $0.65M for the peer group (0.9x).

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

RKDA Sales vs. its Competitors, Q2 2026

Arcadia Biosciences Inc reported revenue contraction of 0.82 % year on year in Q2 2026, above its competitors' combined revenue change of -3.76 %.

With a net margin of -434.23 %, Arcadia Biosciences Inc reported lower profitability than its competitors (28.01 %).

Arcadia Biosciences Inc generated 0.01 % of the combined sales of its peer group, up from 0.01 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/RKDA/competitors
https://api.csimarket.com/api/v1/companies/RKDA/relationships
https://api.csimarket.com/api/v1/companies/RKDA/similar
Programmatic access for models, analytics, and integration workflows.

Arcadia Biosciences Inc vs. its Competitors, Q2 2026

Revenue growth, year on year

Arcadia Biosciences Inc -0.8 %
Competitors combined -3.8 %

Net margin

Arcadia Biosciences Inc -434.2 %
Competitors combined +28.0 %

Revenue run-rate vs trailing 12 months

Arcadia Biosciences Inc +21.6 %
Competitors combined +11.3 %

TTM net margin

Arcadia Biosciences Inc -234.5 %
Competitors combined +9.2 %

TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.

Competitor Financial Benchmarking - TTM Commercial

TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Arcadia Biosciences Inc and its 4 competitor groupings. Available under Commercial License.

Entity TTM Revenue Latest Q ×4 Rev Run-rate vs TTM TTM Net Income TTM Net Margin
Arcadia Biosciences Inc $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Competitors combined $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
High-Confidence Competitors (1) $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Similar-Size Competitors (6) $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Similar Growth & Profitability (1) $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Competitor Financial Benchmarking

TTM revenue, run-rate and net margin benchmarking across Arcadia Biosciences Inc's competitor groups requires a Commercial License.

For context: the Oil And Gas Production industry grew revenue 3.4% year over year, combined, vs -0.8% for Arcadia Biosciences Inc. Arcadia Biosciences Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.

Arcadia Biosciences Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Arcadia Biosciences Inc No No No No
Competitors combined (14) 50% 43% 43% 8%
High-Confidence Competitors (3) 50% 0% 0% 33%
Similar-Size Competitors (9) 25% 40% 60% 78%
Similar Growth & Profitability (8) 0.00 % (0 of 8) 12.50 % (1 of 8) 12.50 % (1 of 8) 57.10 % (4 of 7)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q2 2026

0%market share
  • Arcadia Biosciences Inc0.0%
  • Competitors combined100.0%

Share of combined quarterly revenue of Arcadia Biosciences Inc and its 14 tracked competitors.

See Arcadia Biosciences Inc's full market share breakdown »

RKDA Stock Performance relative to its Competitors

RKDA Competitors (weighted) Percent change over the selected range

Arcadia Biosciences Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
38.5%beat U.S.A. 500
Competitors Combined
(5 of 13)
0%beat U.S.A. 500
High-Confidence
(0 of 2)
0%beat U.S.A. 500
Similar-Size
(0 of 4)
0%beat U.S.A. 500
Similar Growth & Profitability
(0 of 3)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Arcadia Biosciences Inc -92.70 % Underperformed
Competitors combined (13) 40.4% 63.2%
High-Confidence Competitors (2) 40.4% 63.2%
Similar-Size Competitors (4) 40.4% 63.2%
Similar Growth & Profitability (3) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Arcadia Biosciences Inc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

RKDA Stock Performance relative to High-Confidence Competitors

RKDA High-Confidence Competitors (equal-weighted, 3) Percent change over the selected range

RKDA Stock Performance relative to Similar-Size Competitors

RKDA Similar-Size Competitors (equal-weighted, 9) Percent change over the selected range

RKDA Stock Performance relative to Similar Growth & Profitability Competitors

RKDA Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range

5 Best-Performing Tracked Competitors, Trailing 12 Months

#CompetitorTTM Share Price Returnvs U.S.A. 500
1 Dupont De Nemours Inc 282.9% Outperformed
2 Cf Industries Holdings inc 282.9% Outperformed
3 Cibus Inc 282.9% Outperformed
4 Dow Inc 282.9% Outperformed
5 Lsb Industries Inc 282.9% Outperformed
Best-Performing Competitor Returns

TTM share price return and U.S.A. 500 outperformance for Arcadia Biosciences Inc's best-performing tracked competitors requires a Commercial License.

Source: CSIMarket API, trailing 12 months.

Arcadia Biosciences Inc's Comment on Competition and Industry Peers

The markets for seed traits and agricultural biotechnology products are highly competitive, and we face significant direct and indirect competition in several aspects of our business. Competition for improving plant genetics comes from conventional and advanced plant breeding techniques, as well as from the development of

advanced biotechnology traits. Other potentially competitive sources of improvement in crop yields include improvements in crop protection chemicals, fertilizer formulations, farm mechanization, other biotechnology, and information management. Programs to improve genetics and chemistry are generally concentrated within a relatively small number of large companies, while non-genetic approaches are underway with broader set of companies.
In general, we believe that our competitors generally fall into the following categories:


Large Agricultural Biotechnology, Seed, and Chemical Companies: According to Phillips McDougall, the leading 11 seed and trait companies as a group invested $4.1 billion in seed and trait research and development in 2013. This includes conventional and advanced plant breeding, as well as biotechnology trait development. According to Phillips McDougall, only a limited number of companies have been actively involved in new trait discovery, development, and commercialization: Monsanto, DuPont Pioneer, Syngenta, BASF, Bayer, Dow, KWS, and Genective (a joint venture between KWS and Limagrain). Many of these companies have substantially larger budgets for gene discovery, research, development, and product commercialization than we do. Some of these companies also have substantial resources and experience managing the regulatory process for new GM seed traits. Each of Monsanto, DuPont Pioneer, Syngenta, Dow, and Bayer, which accounted for 85% of the 2013 seed trait research and development spend noted above, also have significant chemical crop protection background and businesses. The trait pipelines of these companies are heavily weighted toward biotic stress traits, although they also have significant programs aimed at development of abiotic stress traits. While these companies have internal programs that may compete with our own, they also seek new traits externally and, as such, some of them either currently are, or may in the future be, our collaborators. In addition, some of these companies are currently among our sources for new trait technologies.


Trait Research and Development Companies: There are a number of companies that specialize in research and development of agricultural yield and product quality traits, and we believe that a dozen or more companies, including Evogene and Keygene, among others, are competitors in our field. We believe that these companies typically focus on a limited number of traits, and do not generally have the product development and regulatory infrastructure necessary to bring traits to market. Therefore, they typically license trait technologies to large industry players with in-house development and regulatory capabilities at a relatively early stage of development.


Companies Focused on the Development and Commercialization of Microbial Crop Enhancements: The use of microbial products to enhance crop performance via application to soil, seed, or to crops directly is an area where increased research and development activity has been underway for the past decade or more. We believe that there are more than 20 companies of varying size working in this space. There have been a number of acquisitions, including Becker Underwood by BASF, and joint collaborations in this space, but multiple independent companies remain, including Verdesian, Marrone Bioinnovations, Biagro and Bioconsortia. While these companies could be considered to compete with us as their products seek to improve crop yields, we believe that such products and our traits may be additive, or synergistic, to our future products in terms of increasing crop yields.


Companies Focused on Farming Data Management, or Precision Agriculture: Within the past several years there has been a rapid increase in technologies and companies focused on acquiring, analyzing, and acting upon data in ways that may improve farm economics via increased crop yield and more efficient management of crop production inputs. Technical approaches include weather prediction and monitoring, high-density field and crop imaging systems, precision field soil and yield mapping, and others. Companies focusing on this space include Climate Corporation (acquired by Monsanto), Farmers Business Network, Farmers Edge, Trimble, Planet Labs, Ceres Imaging, Blue River Technologies, and others. While these products are potentially competitive with us for increasing crop yields, we believe that certain of these products could also be additive or synergistic with our traits.


Agricultural Research Universities and Institutions: Given the global importance of agriculture, numerous agricultural research universities and institutions around the world focus on basic and applied research aimed at increasing crop yield. According to the Agricultural Science and Technology Indicators, global public spending on agricultural research and development in 2008 totaled $31.7 billion, having increased by 22% during the years from 2000 to 2008. Spending in 2008 in high income countries accounted for approximately 51% of the total, while spending in low and middle income countries accounted for 49% of the total. The United States was the largest contributor of public agriculture funding in 2008 with a total investment of $4.8 billion. Most of this publicly funded research is focused on basic research. Many public research programs aim to understand basic biological processes and do not necessarily engage in further development and commercialization of discovered traits. While these programs are potentially competitive with us, we view them primarily as sources of innovation that fit with our business model. We have an established track record of working closely and effectively with public research programs, including a number from the U.S., Canada, Japan, Australia, Spain, Ireland, and elsewhere.
We believe that we are uniquely positioned at the nexus of basic research and commercial product development. Unlike many companies in our space, we generally do not compete in the area of basic research. Our focus is on development and validation and, therefore, we provide a value-added link by which basic research can be brought to market. While internal programs at the largest seed and technology companies are competitive with ours in some cases, we are technology providers to some of these companies, and we have numerous collaborations with many of them. To remain competitive, we plan to pursue multiple strategies, including further building our non-GM pipeline of new technologies from basic research programs, increasing the scope and range of our field testing activities, and continuing to protect our intellectual property rights in key jurisdictions globally.

Publicly Traded Peers of Arcadia Biosciences Inc

Revenue and income for trailing 12 months, in millions of $, except employees
Company Market Cap Revenues Income Employees
Arcadia Biosciences Inc 0.84 4.75 -11.13 8
Honeywell International Inc 67,205.48 36,130.00 8,217.00 101,000
Dow Inc 19,861.85 39,331.00 -2,599.00 34,600
Dupont De Nemours Inc 17,768.95 4,701.00 84.00 15,000
Cf Industries Holdings inc 17,735.44 7,739.00 2,500.00 2,900
Eastman Chemical Co 7,476.05 8,865.00 443.00 13,000
SUBTOTAL 144,510.95 122,359.48 4,983.09 188,720
9 more competitors available

Sign in to see all competitors of Arcadia Biosciences Inc .

Sources: Arcadia Biosciences Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Arcadia Biosciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.

Arcadia Biosciences Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Dmc Global Inc Named by the company 85% 2022 to 2026 3
Uphealth Inc Named by the company 85% 2022 to 2026 3
Blue River Technologies Named by the company 85% 2022 to 2026 3
Climate Corporation Named by the company 85% 2022 to 2026 3
Cibus Inc Named by the company 85% 2022 to 2026 3
China Green Agriculture Inc Named by the company 85% 2022 to 2026 3
Marrone Bio Innovations Inc Named by the company 85% 2022 to 2026 3
Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Arcadia Biosciences Inc's named competitors require a Commercial License.

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.

Arcadia Biosciences Inc's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).
Company Largest Segment 2nd Segment 3rd Segment
Dupont De Nemours Inc Diversified Industrials 52.94 % Healthcare and Water Technologies 47.06 % -
Eastman Chemical Co Advanced Materials 32.51 % Additives And Functional Products 32.11 % Chemical Intermediates 25.59 %
Mosaic Co Phosphates 47.57 % Mosaic Fertilizantes 31.26 % Potash 22.26 %
Lsb Industries Inc Chemical 100.00 % - -
Intrepid Potash inc Trio 53.24 % Potash 46.73 % Corporate Segment and Other Operating 0.03 %

Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

2 more Peers available

Sign in to see all peers for Arcadia Biosciences Inc .

Arcadia Biosciences Inc's Productivity vs Peers Comparison

Revenue and income per employee, trailing 12 months, in $; market cap in millions of $
CompanyMarket CapRevenue / EmployeeIncome / Employee
Arcadia Biosciences Inc 1 593,250 -1,391,375
Honeywell International Inc 67,205 357,723 81,356
Dow Inc 19,862 1,136,734 -75,116
Dupont De Nemours Inc 17,769 313,400 5,600
Cf Industries Holdings inc 17,735 2,668,621 862,069
Eastman Chemical Co 7,476 681,923 34,077
PEERS TOTAL 144,510 648,368 26,465
9 more Peers available

Sign in to see all peers for Arcadia Biosciences Inc .

Arcadia Biosciences Inc's Geographic Revenue Exposure vs Peers

Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.
Company Largest Market 2nd Market 3rd Market
Dupont De Nemours Inc United States 44.47 % Asia Pacific 24.96 % EMEA 22.21 %
Mosaic Co United States 39.43 % Brazil 30.85 % Other Foreign 16.21 %
Fmc Corporation EMEA 40.46 % North America 26.05 % Latin America 23.33 %
American Vanguard Corporation US 59.82 % Non Us 40.18 % -
S and w Seed Co AR 1.86 % MX 1.10 % -

Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.

Arcadia Biosciences Inc's Position in Industry Market Structure

Market-capitalization share and concentration across all 113 companies in Arcadia Biosciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.

Arcadia Biosciences Inc ranks #109 of 113 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 782, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).

Rank Company Market Cap Industry Share
1 Shell Plc 285,373 19.14 %
2 Totalenergies Se 205,002 13.75 %
3 Canadian Natural Resources Limited 103,756 6.96 %
4 Eni Spa 93,902 6.30 %
5 Slb Limited 1,234 5.2%
6 Eog Resources Inc 1,234 5.2%
7 Occidental Petroleum Corporation 1,234 5.2%
8 Cenovus Energy Inc 1,234 5.2%
9 Diamondback Energy Inc 1,234 5.2%
10 Devon Energy Corp 1,234 5.2%
109 Arcadia Biosciences Inc 1 0.00 %
Full Industry Market Structure

Market cap and industry share for the rest of Arcadia Biosciences Inc's industry peers requires a Commercial License.

Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-30.

Arcadia Biosciences Inc's Same-Size Peers & Stock Performance

Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.
Rank Company Market Cap TTM Return 3M Momentum Beta Sharpe (1Y)
104 Barnwell Industries inc 13 -30.71 % -5.77 % 0.05 -0.19
105 Royale Energy Inc 10 - - -0.66 1.51
106 Camber Energy Inc 8 -48.00 % 30.00 % -0.22 -0.49
107 New Concept Energy Inc 4 -29.81 % 5.80 % -0.03 0.28
108 Altex Industries Inc 1,234 12.3% 4.5% 1.10 0.80
109 Arcadia Biosciences Inc 1 -92.71 % -64.31 % 0.67 -1.74
110 Groove Botanicals Inc 1,234 12.3% 4.5% 1.10 0.80
111 Kolibri Global Energy Inc 1,234 12.3% 4.5% 1.10 0.80
112 Gulfslope Energy Inc 1,234 12.3% 4.5% 1.10 0.80
113 Himalaya Technologies Inc 1,234 12.3% 4.5% 1.10 0.80
Full Same-Size Peer Performance

Market cap, return, momentum, beta and Sharpe ratio for the rest of Arcadia Biosciences Inc's same-size peers requires a Commercial License.

Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-30. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.

Arcadia Biosciences Inc's Profitability & Cost Structure

Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Oil And Gas Production industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (170 companies). See the full Oil And Gas Production industry profitability benchmarks.
Metric Company Industry Difference
Gross Margin 34.60 % 55.47 % (avg) -20.9 pp
Operating Margin -80.15 % industry median -91.6 pp
EBITDA Margin -112.33 % 11.68 % (avg) -124.0 pp
Capital Intensity (Capex / Revenue) 0.00 % 24.49 % (avg) -24.5 pp

Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.

Arcadia Biosciences Inc's Valuation vs Competitive Position

Valuation multiples vs the Oil And Gas Production industry average (170 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Oil And Gas Production industry valuation benchmarks.
Metric Company Industry Average Difference
P/E - 15.6x -
EV / EBITDA - 9.0x -
P/B 0.8x 1.8x -1.0x
Return on Equity -339.85 % industry aggregate -351.84 %
Return on Invested Capital -47.41 % 5.18 % (avg) -52.59 %

Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.

Arcadia Biosciences Inc's Multi-Year Financial Trajectory

Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.
Metric 20182019202020212022202320242025
Revenue Growth -63.64 %-20.15 %500.00 %-15.61 %46.84 %-46.46 %-5.35 %-3.71 %
Operating Margin -1,152.32 %-1,657.91 %-159.05 %-523.98 %-188.98 %-261.50 %-72.31 %-51.46 %
Return on Invested Capital -52.78 %-59.13 %-26.48 %-37.15 %-33.89 %-38.01 %-16.27 %-19.79 %
P/E --------

Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.

Arcadia Biosciences Inc's Strategic Group Map

Every company in Arcadia Biosciences Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Arcadia Biosciences Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.

Revenue Growth (TTM, %)Operating Margin (%)AGPVTLEFMCEXXIGSTSWNArcadia Biosciences IncRCONBBEP

Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.

Arcadia Biosciences Inc's BCG Growth-Share Matrix

Relative market share (vs Arcadia Biosciences Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.

Question Mark Star Dog Cash Cow Relative Market Share (vs largest competitor) Industry Revenue Growth (%) Arcadia Biosciences Inc

Arcadia Biosciences Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue -0.2% (median, trailing 12 months).

Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.

Arcadia Biosciences Inc's Competitive Forces (Porter's Five Forces)

Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.
Force Assessment Basis
Competitive Rivalry High Industry HHI of 782 (see Industry Market Structure & Concentration above)
Barriers to Entry Lower than typical for the industry Capital intensity (capex / revenue) of 0.00 % vs industry average 24.49 % (see Profitability & Cost Structure above)
Supplier Power Not covered on this page See Arcadia Biosciences Inc's dedicated suppliers page for concentration and dependency data
Buyer Power Not covered on this page See Arcadia Biosciences Inc's dedicated customers page for concentration and dependency data
Threat of Substitutes - No systematic data source for cross-product substitution exists in this system; not estimated

Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.

Arcadia Biosciences Inc's Industry Attractiveness & Competitive Strength

A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.

High Strength
Medium Strength
Low Strength
High Attractiveness
Invest / Grow
Invest / Grow
Selective
Medium Attractiveness
Invest / Grow
Selective
Harvest
Low Attractiveness
Selective
Harvest
Harvest / Divest Arcadia Biosciences Inc

Arcadia Biosciences Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.

Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.

Arcadia Biosciences Inc's SWOT

Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.

Strengths

  • Latest-quarter revenue run-rate is accelerating (+21.6% annualized vs trailing 12 months).

Weaknesses

  • Operating margin 91.6 points below the industry median.
  • Return on equity 351.8 points below the industry aggregate.
  • Underperforming the U.S.A. 500 over the trailing 12 months.
  • Low relative market share vs the industry leader (0.00x).

Opportunities

No rule matched.

Threats

No rule matched.

Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.

Arcadia Biosciences Inc's Financial Strength vs Peers Comparison

Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months
CompanyQuick RatioWorking CapitalDebt / EquityAsset Turnover
Arcadia Biosciences Inc 0.89 3.49 - 0.72
Honeywell International Inc 0.51 1.31 2.10 0.47
Dow Inc 0.37 1.86 0.99 0.66
Dupont De Nemours Inc 0.62 2.29 0.28 0.18
Cf Industries Holdings inc 0.17 3.34 0.39 0.53
Eastman Chemical Co 0.05 1.51 0.84 0.59
9 more Peers available

Sign in to see all peers for Arcadia Biosciences Inc .

Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.

Arcadia Biosciences Inc's Revenue and Income Growth vs Peers

Quarterly revenue and net income growth, year over year and quarter over quarter
CompanyPeriodRevenue Y/YRevenue Q/QIncome Y/YIncome Q/Q
Arcadia Biosciences Inc Q2 2026-0.8 %+31.2 %--
Honeywell International IncQ2 2026-6.1 %+6.3 %+262.4 %+615.2 %
Dow Inc Q1 2026-6.1 %+3.5 %--
Dupont De Nemours Inc Q2 2026-44.2 %+8.2 %+110.0 %-10.4 %
Cf Industries Holdings inc Q2 2026+17.6 %+11.9 %+76.6 %+28.6 %
Eastman Chemical CoQ2 2026+9.9 %+15.4 %+31.4 %+72.0 %
PEERS TOTAL-4.5 %+7.4 %+156.6 %+8,101.2 %
9 more Peers available

Sign in to see all peers for Arcadia Biosciences Inc .

Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.

Arcadia Biosciences Inc's Peers' Costs of Sales and Capital Expenditures

Context for revenue growth: peer costs and capex, year over year and quarter over quarter
CompanyPeriodCosts Y/YCosts Q/QCapex Y/YCapex Q/Q
Arcadia Biosciences Inc Q2 2026-1.5 %+16.0 %--
Honeywell International IncQ2 2026+7.2 %+8.2 %+39.4 %+41.3 %
Dow Inc Q1 2026-6.2 %+2.7 %-26.7 %-14.8 %
Dupont De Nemours Inc Q2 2026+3.2 %+9.4 %+52.0 %-25.5 %
Cf Industries Holdings inc Q2 2026-5.1 %-13.1 %+10.6 %+21.5 %
Eastman Chemical CoQ2 2026+9.7 %+11.9 %-33.3 %-2.9 %
9 more Peers available

Sign in to see all peers for Arcadia Biosciences Inc .

Arcadia Biosciences Inc's Returns and Turnover vs Peers

ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover
CompanyROAROIROEReceivables TurnoverInventory Turnover
Arcadia Biosciences Inc ---8.482.80
Honeywell International Inc10.74%17.01%49.57%4.393.52
Dow Inc ---7.715.51
Dupont De Nemours Inc 0.33%0.36%0.51%2.513.34
Cf Industries Holdings inc 17.24%15.64%30.63%12.2211.59
Eastman Chemical Co2.93%3.40%7.34%9.543.51
9 more Peers available

Sign in to see all peers for Arcadia Biosciences Inc .

ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).

Arcadia Biosciences Inc's Valuation vs Peers

P/E, price to sales, PEG, price to cash flow and price to book
CompanyP/EPrice / SalesPEGP/CFPrice / Book
Arcadia Biosciences Inc -0.18-0.301.32
Honeywell International Inc8.291.860.15-3.56
Dow Inc -0.50-7.411.18
Dupont De Nemours Inc 288.643.78--1.28
Cf Industries Holdings inc 8.612.290.1122.341.99
Eastman Chemical Co16.930.84-27.901.21
PEERS AVERAGE29.001.1861.121.81
9 more Peers available

Sign in to see all peers for Arcadia Biosciences Inc .

P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.

Get the full CSIMarket dataset: Subscribe API License